TriSalus Life Sciences, Inc.
TLSIW- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
No open-market purchases or sales by TriSalus Life Sciences, Inc. insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $798.0K in total; no superinvestor holds it.
Other share classesTLSI
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 5
- 13F valueReported value at the end of Q2 2026
- $798.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TLSIW, Q2 2026
No superinvestor reported holding TLSIW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by TriSalus Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 15 | 4 days | Marshak RichardChief Commercial Officer | SSale | −543 | $2.67 | −$1.45K | −0.4%125.1K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Wahlstrom MatsDirector | PPurchase | +60.0K | $2.53 | +$151.8K | +68.5%147.6K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +410.0K | $2.50 | +$1.02M | +49.4%1.24M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +200.0K | $2.50 | +$500.0K | +100.2%399.7K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Szela Mary TCEO and President | PPurchase | +39.7K | $2.59 | +$102.8K | +3.9%1.07M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Patience DavidChief Financial Officer | PPurchase | +7.10K | $2.43 | +$17.3K | +2.6%275.8K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Gordon Gary B.Director | PPurchase | +10.0K | $2.46 | +$24.6K | +16.0%72.5K after | |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Devlin JodiChief of Clinical Operations | SSale | −3.21K | $4.11 | −$13.2K | −3.2%97.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Cox Bryan F.Chief of Research | SSale | −3.18K | $4.11 | −$13.1K | −1.9%163.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Marshak RichardChief Commercial Officer | SSale | −3.46K | $4.11 | −$14.2K | −3.0%110.4K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in TriSalus Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cerity Partners LLC | 827,590 | $662.1K | 0.00% | 00.0% | Unchanged |
| Aristeia Capital LLC | 74,826 | $56.9K | 0.00% | +46,210+161.5% | Added |
| Vestcor Inc | 70,832 | $54.0K | 0.00% | 00.0% | Unchanged |
| Fort Baker Capital Management LP | 26,374 | $21.1K | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 5,170 | $3.93K | 0.00% | 00.0% | Unchanged |